# A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

Source: https://onco.cc/trials/nct04995523/  
OnCo record `nct04995523` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Rilvegostomig in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC is a phase 1/2 interventional study registered as NCT04995523 by AstraZeneca, with 212 participants enrolled, started 2021-09-14 and due to reach its primary completion in 2026-08-28. Interventions recorded: AZD2936.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04995523
- Phase: 1/2
- Setting: Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
- Sponsor: AstraZeneca
- Enrolled: 212

## Sources

- ClinicalTrials.gov NCT04995523: https://clinicaltrials.gov/study/NCT04995523

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Rilvegostomig](https://onco.cc/drugs/rilvegostomig/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct04995523.json